Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Eur J Haematol. 2020 Mar;104(3):162-169. doi: 10.1111/ejh.13346. Epub 2020 Jan 22.

Abstract

Objective: The obesity/overweight may have an influence on APL outcomes.

Methods: This is the biggest multicentre analysis on 1320 APL patients treated with AIDA-induction and risk-adapted consolidation between 1996 and 2012. Patients body mass index (BMI) was classified as underweight (<18.5 kg/m2 ), normal (18.5-25 kg/m2 ), overweight (25-29.9 kg/m2 ), and obese (≥30 kg/m2 ) according to the World Health Organization (WHO) criteria.

Results and conclusions: Relationship between male gender, older age, and other known laboratory abnormalities in overweight/obese patients was significant. The induction mortality rate was significantly higher in APL with BMI ≥25 vs BMI <25 (10% vs 6%; P = .04). APL patients with BMI ≥25 had a trend to lower OS (74% vs 80%; P = .06). However, in the multivariate analysis, BMI did not retain the independent predictive value (P = .46). There was no higher incidence of differentiation syndrome with BMI ≥25, but there was a trend in obese. There was no difference in relapse rate according to the BMI. In summary, overweight/obesity does not represent an independent risk factor for APL outcomes. The influence of obesity in APL patients treated with chemotherapy-free regimens remains to be established.

Keywords: AIDA protocol; acute promyelocytic leukemia; obesity; outcome.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asparaginase / adverse effects
  • Asparaginase / therapeutic use
  • Body Mass Index
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Leukemia, Promyelocytic, Acute / epidemiology*
  • Leukemia, Promyelocytic, Acute / mortality
  • Male
  • Mercaptopurine / adverse effects
  • Mercaptopurine / therapeutic use
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use
  • Middle Aged
  • Obesity
  • Population Surveillance
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Prognosis
  • Recurrence
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use
  • Young Adult

Substances

  • Vincristine
  • Mercaptopurine
  • Asparaginase
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CCG-141 protocol